title: Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome.
abstract: Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan. Previous reports have shown that affected patients typically respond to immunosuppressive therapy, such as prednisolone and tocilizumab. However, the optimal treatment for refractory TAFRO syndrome, which can be fatal, remains unclear. We herein report a case of tocilizumab-resistant TAFRO syndrome successfully treated with cyclosporin A, indicating that cyclosporine A may be an alternative therapy for refractory TAFRO syndrome.
authors.affiliation: Department of General Internal Medicine, Matsunami General Hospital, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yamaga
authors.forename: Kiyonobu
authors.initials: K
authors.lastname: Tokuyama
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kato
authors.forename: Rie
authors.initials: R
authors.lastname: Yamada
authors.forename: Masanori
authors.initials: M
authors.lastname: Murayama
authors.forename: Tsuneko
authors.initials: T
authors.lastname: Ikeda
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Yamakita
authors.forename: Takeshige
authors.initials: T
authors.lastname: Kunieda
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C502936:tocilizumab